Weight loss, Metabolism diseases
Weight loss, Metabolism diseases
Regulate energy balance and increase basal metabolic rate
Efficacy data from mice showed that, under a high-fat diet, the mice exhibited:
The optimization of these indicators suggests that the mice became healthier.
The global development of weight loss drugs focuses on medications that prevent muscle loss. According to statistics from market analysis agencies, the number of global patients with obesity and fatty liver is approximately 3 billion and 2 billion, respectively. The global market is estimated to reach $100 billion by 2030 and $32.5 billion by 2032.
Research Code | Therapeutic Area | Indication | Pre-Clinical | Phase I | Phase II | Phase III | NDA | Market | More |
---|
SNS851 is an innovative siRNA drug for weight loss and improving metabolism-related markers. Efficacy data from mouse studies showed that even under a high-fat diet, mice exhibited increased basal metabolic rate, no weight gain, reduced fat accumulation, improvement in the severity of fatty liver, significant improvements in blood lipids and blood glucose markers, and no reduction in muscle mass, indicating that the mice became healthier.
建議您使用以下瀏覽器觀看合一網站,
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?